Roche (RHHBY) has announced that the European Medicines Agency has granted approval for Vabysmo, or faricimab, as a single-dose prefilled syringe containing 6.0 mg. This medication is intended for treating conditions such as neovascular or 'wet' age-related macular degeneration, diabetic macular edema, and macular edema resulting from retinal vein occlusion. The prefilled syringe format of Vabysmo offers the same therapeutic solution as the existing 6.0 mg Vabysmo vials but in a more convenient, ready-to-use form. Roche highlighted that Vabysmo PFS is notable for being the first and only CE-labelled needle designed specifically for intravitreal injection, enhancing ophthalmologists' treatment options.
Levi Garraway, the Chief Medical Officer and Head of Global Product Development at Roche, stated: "This streamlined administration approach may help lessen the treatment demands on patients and retina specialists alike."
The material has been provided by InstaForex Company - www.instaforex.com
Levi Garraway, the Chief Medical Officer and Head of Global Product Development at Roche, stated: "This streamlined administration approach may help lessen the treatment demands on patients and retina specialists alike."
The material has been provided by InstaForex Company - www.instaforex.com